To give you the best experience, this site uses cookies. Learn more about cookies
Discover. Prevent. Cure.
We're searching for answers to some of the most common and complex childhood diseases, conditions and issues. In addition to our four research themes (Indigenous Health, Brain and Behaviour, Chronic and Severe Diseases, Early Environment), you can also discover more about specific research we're involved in and the technology we use.
Discover what drives us as an organisation. Learn about history and the impact of the Institute along with the amazing ambitious goals we've achieved so far in the field of children's research.
Join us! Get involved with Telethon Kids through providing a donation, volunteering your time, participating in important research, or with a professional commitment to the institute.
Different audiences rely on us for very different things. Whether you're a valued donor, curious professional researcher, inquisitive member of the public, or a corporate supplier looking to offer support - we've collated the resources you need.
Keywords:
Abstract:
Despite living in an era of evidence-based medicine and austerity, where every health dollar must be justified, the use of humidified high-flow nasal cannula oxygen (HFNC) in children with bronchiolitis has become increasingly prevalent,1 with limited evidence to substantiate its clinical benefit or economic worth. Current National Institute for Health and Care Excellence (NICE 2015) guidelines for bronchiolitis state that ‘the use of this medical device is becoming widespread without demonstration of additional efficacy’. Recent studies by Kepreotes et al 2 and Riese et al 3 have shown that the use of ward-based HFNC in children with bronchiolitis did not reduce the hospital length of stay (LOS) or rate of admission to the paediatric intensive care unit (PICU), when compared with standard low-flow oxygen therapy.
We undertook a retrospective pre–post cohort study of infants aged ≤12 months with bronchiolitis who were admitted to a tertiary Australian paediatric hospital. A period of 12 months prior to the widespread use of HFNC (January–December 2012) was compared with a 12-month period following the establishment of HFNC as a ward-based treatment escalation modality for children with bronchiolitis (January–December 2015). The commencement of HFNC was considered for clinical signs of persistent or worsening hypoxia and respiratory distress despite standard flow oxygen at the discretion of the treating clinician; objective measures of respiratory failure were not a prerequisite to commencing HFNC. Admission data (age, LOS, oxygen support modality and PICU admission) for infants ≤12 months with bronchiolitis without significant preexisting comorbidities (eg, congenital cardiac disease, chronic lung disease and chronic neurological disorders) were obtained from electronic discharge summaries. Bronchiolitis was categorised as mild (no respiratory support), moderate (oxygen therapy in any combination of low-flow nasal prong oxygen, head-box oxygen or HFNC) or severe (requiring continuous positive airway pressure (CPAP) and/or invasive positive pressure ventilation (IPPV)) for subanalysis.